Discovery Behavioral Health Opens Treatment Center for Eating Disorders in Milwaukee – Yahoo Finance

Center For Discovery Provides Outpatient and Residential Treatment
LOS ANGELES, Dec. 8, 2022 /PRNewswire/ — Discovery Behavioral Health, Inc., an expanding network of evidence-based mental health, substance use and eating disorder treatment centers, has opened a new, 48-bed facility in the heart of downtown Milwaukee. Located in a seven-story high-rise, the facility will offer programs for adults under the Center For Discovery (https://centerfordiscovery.com/locations/milwaukee-wi/) brand name.
“Discovery Behavioral Health is helping to fill Wisconsin’s significant need for mental health services.”
Staffed by healthcare professionals and support personnel, the center offers both outpatient and residential care, and is conveniently located in either walking distance or a short bus ride from leading higher education schools, including Marquette University, University of Wisconsin Milwaukee, Milwaukee School of Engineering and Milwaukee Area Technical College. The facilities include group and individual treatment meeting rooms, café seating for meals and a full-size commercial kitchen.
The center will be headed by seasoned behavioral health executive Amanda Vogt, CEO, who previously worked for 22 years at Rogers Behavioral Health. She earned her bachelor’s degree from the University of Wisconsin, Milwaukee, and her master’s degree in social work from Aurora University. “Eating disorders are a specific type of behavioral health disorder that require specialized clinical interventions. Today, as we continue with the demand for mental health that have continued to surge since the pandemic, we are committed to being good partners in the community by building relationships with patients and their families as well as fellow healthcare professionals. We are eager to support and work with the people in this region, throughout Wisconsin and surrounding states,” says Vogt.
State Senator LaTonya Johnson (D – 6th Senate District) stated, “Discovery Behavioral Health is helping to fill Wisconsin’s significant need for mental health services. Our state has 859,000 adults with a mental health condition – many of them without good treatment options. In these turbulent times, accessibility to mental health services is vital to give people every opportunity to build better lives, healthier families, and stronger communities.”
Dr. John Peloquin, Chief Executive Officer of Discovery Behavioral Health said, “I’d like to thank Governor Tony Evers, his staff and the people at Wisconsin Department of Health Services for their guidance as this service was established. We look forward to working with them in the future to understand and address the State’s needs.”
Discovery Behavioral Health President & CEO John Peloquin notes, “For 25 years, Center For Discovery has provided compassionate and evidence-based treatment to those in need. We are pleased to expand access to quality care with our newest facility in Milwaukee.”
About Discovery Behavioral Health
Everyone deserves a happy, rewarding life. That’s why Discovery Behavioral Health has made evidence-based, outcome driven healthcare accessible and affordable since inception. With a full continuum of care – detoxification, medical residences, residential treatment centers, partial hospitalization, intensive outpatient, outpatient, psychiatric and addiction medicine, TMS, virtual and telehealth services, we can offer the right care at the right time for adults or teens struggling with mental health, substance use or eating disorders. With a portfolio of more than 154 treatment centers including service lines in successful operation since 1985, we are a preferred and trusted provider with most insurance companies who value our clinical rigor and remarkable results. When treatment is complete, our patients become part of Discovery’s growing family of Alumni, connected through free aftercare programs, support groups, activities, and a caring community – for life – because when quality behavioral healthcare is within reach, so is happiness.
Press Contact:
Greg Ptacek
PR | Communications
Discovery Behavioral Health, Inc.
323-841-8002 mobile
gPtacek@discoverybh.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/discovery-behavioral-health-opens-treatment-center-for-eating-disorders-in-milwaukee-301697759.html
SOURCE Discovery Behavioral Health
Pat Hughes, who spent 12 years calling Brewers games with Bob Uecker, was given a major honor from the National Baseball Hall of Fame.
Shares of BioVie (NASDAQ: BIVI) were soaring 23.6% higher as of 11:19 a.m. ET on Thursday. The big jump appears to be the result of a delayed positive reaction by investors after the drugmaker reported results earlier this week from a phase 2 study evaluating experimental therapy NE3107. On Tuesday, BioVie's share price tumbled after the company's Monday evening announcement of results from its phase 2 study of NE3107 in treating Alzheimer's disease and Parkinson's disease.
Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Johnson & Johnson (NYSE: JNJ) have all been doing so. Eli Lilly and CRISPR are developing radical new therapies, while Johnson & Johnson is going all-in on using artificial intelligence to bring new therapies to market more quickly. It's hard to see Eli Lilly as a revolutionary stock.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript December 5, 2022 Veru Inc. misses on earnings expectations. Reported EPS is $-0.51 EPS, expectations were $-0.3. Operator: Good morning ladies and gentlemen, and welcome to Veru Inc.’s Investor Conference Call. All participants will be in listen-only mode. After this morning’s discussion, there will be an opportunity […]
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.
Under the decision, certain children 6 months through 5 years can get the updated boosters, which target two Omicron offshoots as well as the original strain of the coronavirus.
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.
Here are the most common symptoms that researchers found.
We all know the holidays can be stressful, but did you know December brings the most cardiac deaths of any month? Find out why and what you can do to prevent that number from rising.
For years, the rates of anxiety — and the use of a fast-acting prescription drug to alleviate its symptoms — have been on the rise.
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales. With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective. Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
“Whenever you have a large wave of transmissions of a virus, you give it ample opportunity to mutate,” he said.
Vitamin D may reduce the risk of dementia by up to a third, a study has suggested.
Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. On Monday, the company released early phase 2 data on Adagrasib to treat non-small cell lung cancer (NSCLC), along with Keytruda, which is sold by Merck (NYSE: MRK). On Wednesday, Mirati presented the data from its Krystal 7 and Krystal 1 trials with Adagrasib, at the 2022 ESMO Immuno-Oncology Annual Congress.
Being proactive about brain health is one way to live a longer quality of life and help reduce the risk of dementia. According to the World Health Organization, more than 55 million people worldwide are living with the crippling condition that can rob your memory, judgment and performing day-to-day activities. WHO states, "Dementia is currently the seventh leading cause of death among all diseases and one of the major causes of disability and dependency among older people globally.""The brain is

source